Antitopoisomerase drug action and resistance.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Cancer

• Publication date

  1996-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0959-8049(96)00056-1PMID 8763336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells

  2012cited by this paper
• DNA Topoisomerase II Is Required at the Time of Mitosis in Yeast

  2004cited by this paper
• Using yeast to study resistance to topoisomerase II-targeting drugs

  2004cited by this paper
• Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.

  1996cited by this paper
• p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis.

  1995cited by this paper
• DNA topoisomerase II mutations and resistance to anti‐tumor drugs

  1995cited by this paper
• Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.

  1995cited by this paper
• p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis.

  1995cited by this paper
• Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.

  1995cited by this paper
• A Yeast Type II Topoisomerase Selected for Resistance to Quinolones

  1995cited by this paper
• p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts.

  1995cited by this paper
• Taxol induction of p21WAF1 and p53 requires c-raf-1.

  1995cited by this paper
• Expression of bcl-xL can confer a multidrug resistance phenotype.

  1995cited by this paper
• Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*)

  1995cited by this paper
• Bcl-2: prevention of apoptosis as a mechanism of drug resistance.

  1995cited by this paper
• The drug resistance-related protein LRP is the human major vault protein

  1995cited by this paper
• P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.

  1995cited by this paper
• Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.

  1995cited by this paper
• DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.

  1995cited by this paper
• Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

  1995cited by this paper
• Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation.

  1995cited by this paper
• Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.

  1994cited by this paper
• Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.

  1994cited by this paper
• Cell cycle control and cancer.

  1994cited by this paper
• DNA topoisomerases: essential enzymes and lethal targets.

  1994cited by this paper
• Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways.

  1994cited by this paper
• Cell cycle control and cancer chemotherapy

  1994cited by this paper
• Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia

  1994cited by this paper
• Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.

  1994cited by this paper
• Yeast as a genetic model system for studying topoisomerase inhibitors.

  1994cited by this paper
• Phase II study of topotecan in metastatic non-small-cell lung cancer.

  1994cited by this paper
• c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle.

  1994cited by this paper
• Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer

  1994cited by this paper
• Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors

  1994cited by this paper
• Multidrug resistance in the laboratory and clinic.

  1994cited by this paper
• Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance.

  1994cited by this paper
• Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.

  1994cited by this paper
• A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells

  1994cited by this paper
• Checkpoints of dueling dimers foil death wishes.

  1994cited by this paper
• Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events

  1994cited by this paper
• Mechanism of action of topoisomerase II-targeted antineoplastic drugs.

  1994cited by this paper
• A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.

  1994cited by this paper
• Cellular regulation of mammalian DNA topoisomerases.

  1994cited by this paper
• Drug resistance mechanisms of topoisomerase I drugs.

  1994cited by this paper
• Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene.

  1994cited by this paper
• Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.

  1994cited by this paper
• Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.

  1994cited by this paper
• Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer.

  1994cited by this paper
• Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.

  1994cited by this paper
• Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.

  1994cited by this paper
• Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.

  1994cited by this paper
• Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.

  1994cited by this paper
• Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

  1994cited by this paper
• Mechanisms of topoisomerase I inhibition by anticancer drugs.

  1994cited by this paper
• Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.

  1994cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs.

  1993cited by this paper
• Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia.

  1993cited by this paper
• A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.

  1993cited by this paper
• Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.

  1993cited by this paper
• Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.

  1993cited by this paper
• The role of topoisomerase II alpha and beta in drug resistance.

  1993cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.

  1993cited by this paper
• DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.

  1993cited by this paper
• The role of topoisomerase IIα and β in drug resistance

  1993cited by this paper
• Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.

  1993cited by this paper
• Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.

  1992cited by this paper
• Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.

  1992cited by this paper
• Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.

  1992cited by this paper
• Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I.

  1992cited by this paper
• Creative blocks: cell-cycle checkpoints and feedback controls

  1992cited by this paper
• DNA topoisomerase II: a review of its involvement in chromosome structure, DNA replication, transcription and mitosis.

  1992cited by this paper
• Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.

  1992cited by this paper
• Catalytic function of DNA topoisomerase II

  1991cited by this paper
• DNA gyrase: structure and function.

  1991cited by this paper
• Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.

  1991cited by this paper
• Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.

  1991cited by this paper
• DNA topoisomerases: why so many?

  1991cited by this paper
• Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding.

  1991cited by this paper
• Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

  1991cited by this paper
• Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.

  1991cited by this paper
• Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide.

  1991cited by this paper
• Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.

  1991cited by this paper
• Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

  1991cited by this paper
• Fluoroquinolone antimicrobial agents.

  1991cited by this paper
• The role of DNA topoisomerases in recombination and genome stability: a double-edged sword?

  1990cited by this paper
• HPR1, a novel yeast gene that prevents intrachromosomal excision recombination, shows carboxy-terminal homology to the Saccharomyces cerevisiae TOP1 gene

  1990cited by this paper
• Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei.

  1990cited by this paper
• A novel pathway of DNA end-to-end joining.

  1990cited by this paper
• A model for tumor cell killing by topoisomerase poisons.

  1990cited by this paper
• DNA topology and its biological effects

  1990cited by this paper
• Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers.

  1990cited by this paper
• Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

  1989cited by this paper
• Checkpoints: controls that ensure the order of cell cycle events.

  1989cited by this paper
• Fluoroquinolone antimicrobial agents

  1989cited by this paper
• DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

  1989cited by this paper
• In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

  1989cited by this paper
• A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase.

  1989cited by this paper
• DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage

  1989cited by this paper

• Yeast Tools for Studying Type II Topoisomerases in Budding Yeast.

  2025cites this paper
• Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

  2024cites this paper
• Evaluation of Genotoxic Effects of N-Methyl-N-Nitroso-Urea and Etoposide on the Differentiation Potential of MSCs from Umbilical Cord Blood and Bone Marrow

  2024cites this paper
• Development of β‐Carboline‐Coumarin Based Hybrids as Potential Cytotoxic and Topoisomerase IIα Inhibitors

  2024cites this paper
• Design, synthesis and in vitro cytotoxic evaluation of β-carboline tethered quinoline-4-carboxamide conjugates as DNA-interactive Topo II inhibitors

  2023cites this paper
• Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.

  2023cites this paper
• Synthesis and cytotoxicity evaluation of DNA-interactive β-carboline indolyl-3-glyoxamide derivatives: Topo-II inhibition and in silico modelling studies.

  2022cites this paper
• Design, synthesis of DNA-interactive 4-thiazolidinone-based indolo-/pyrroloazepinone conjugates as potential cytotoxic and topoisomerase I inhibitors.

  2022cites this paper
• Evolutionary History of TOPIIA Topoisomerases in Animals

  2022cites this paper
• Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

  2022cites this paper
• Inhibition of Aedes aegypti DNA topoisomerase II by etoposide: Impact on survival and morphology of larvae and pupae.

  2021cites this paper
• Topoisomerase Assays

  2021cites this paper
• Resistance to Antimicrobial Agents: From Bacteria to Yeast

  2021cites this paper
• Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.

  2020cites this paper
• FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.

  2020cites this paper
• Development of β-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIα inhibition and apoptosis induction.

  2020cites this paper
• Design and synthesis of β-carboline linked aryl sulfonyl piperazine derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability.

  2020cites this paper
• Synthesis and in vitro cytotoxicity evaluation of β-carboline-combretastatin carboxamides as apoptosis inducing agents: DNA intercalation and topoisomerase-II inhibition.

  2019cites this paper
• Design and synthesis of DNA-intercalative naphthalimide-benzothiazole/cinnamide derivatives: cytotoxicity evaluation and topoisomerase-IIα inhibition.

  2019cites this paper
• Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.

  2018cites this paper
• Synthesis of Novel Pyrazole Derivatives as Promising DNA-Binding Agents and Evaluation of Antitumor and Antitopoisomerases I/II Activities.

  2018cites this paper
• An efficient one-pot approach for the regio- and diastereoselective synthesis of trans-dihydrofuran derivatives: cytotoxicity and DNA-binding studies.

  2017cites this paper
• Measurement of Drug‐Stabilized Topoisomerase II Cleavage Complexes by Flow Cytometry

  2017cites this paper
• MYCN, proliferative heterogeneity and treatment responsein neuroblastoma

  2017cites this paper
• Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints.

  2017cites this paper
• 2-aryl benzimidazole conjugate induced apoptosis in human breast cancer MCF-7 cells through caspase independent pathway

  2016cites this paper
• Physical Proximity of Sister Chromatids Promotes Top2-Dependent Intertwining

  2016cites this paper
• Inhibition of DNA Topoisomerase Type IIα (TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study

  2016cites this paper
• A flow cytometry‐based method for a high‐throughput analysis of drug‐stabilized topoisomerase II cleavage complexes in human cells

  2016cites this paper
• STUDI IN SILICO CONVERSE REGION ETOPOSITE BINDING DOMAIN Pada ISOZIM HUMAN DNA TOPOISOMERASE II

  2016cites this paper
• Identification of doxorubicin drug resistance mechanisms by using genomic techniques

  2015cites this paper
• Synthesis, molecular structure, DNA interaction and antioxidant activity of novel naphthoxazole compound.

  2014cites this paper
• CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.

  2014influential citation
• Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells

  2013cites this paper
• Topoisomerase as target for antibacterial and anticancer drug discovery

  2013cites this paper
• Topoisomerase II Inhibitors: Chemical Biology

  2012cites this paper
• Topoisomerase Assays

  2012cites this paper
• Repair of Topoisomerase II-Mediated DNA Damage: Fixing DNA Damage Arising from a Protein Covalently Trapped on DNA

  2012cites this paper
• Novel Regulation of Nuclear Factor-YB by miR-485-3p Affects the Expression of DNA Topoisomerase IIα and Drug Responsiveness

  2011cites this paper
• High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment

  2010influential citation
• Intrinsic Resistance to Chemotherapy in Breast Cancer

  2010cites this paper
• Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.

  2010cites this paper
• MECHANISMS OF MITOCHONDRIA-MEDIATED APOPTOSIS INDUCED BY CYTOTOXIC STRESS

  2010cites this paper
• Biological markers in breast cancer and acute leukaemia

  2010cites this paper
• Simultaneous drug release at different rates from biodegradable polyurethane foams.

  2009cites this paper
• Heterozygous disruption of the DNA topoisomerase I gene confers cellular resistance to camptothecin in human cells.

  2009cites this paper
• Targeting DNA topoisomerase II in cancer chemotherapy

  2009cites this paper
• Prognostic and predictive factors.

  2009cites this paper
• BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress.

  2008cites this paper
• Drug resistance in acute myeloid leukemia : Clinical and experimental studies

  2008cites this paper
• Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview

  2008cites this paper
• Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.

  2008cites this paper
• The Requirement of Artemis in Double-Strand Break Repair Depends on the Type of DNA Damage

  2008cites this paper
• A novel peroxisome proliferator-activated receptor &agr;/&ggr; agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells

  2008cites this paper
• Isolation and Characterization of mAMSA-hypersensitive Mutants

  2008cites this paper
• BRCA1-Mediated Ubiquitination Inhibits Topoisomerase IIα Activity in Response to Oxidative Stress

  2008cites this paper
• Etoposide‐resistant HT‐29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down‐regulator

  2008cites this paper
• DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA

  2008cites this paper
• Dihydropyridine Derivatives to Overcome Atypical Multidrug Resistance: Design, Synthesis, QSAR Studies, and Evaluation of Their Cytotoxic and Pharmacological Activities

  2007influential citation
• 11 Regulatory Aspects of the Oncology Drug Diagnostics Co-Development Process by Proteomics Approach

  2007cites this paper
• Mithramycin inhibits etoposide resistance in glucose-deprived HT-29 human colon carcinoma cells.

  2007cites this paper
• Gam1-associated alterations of drug responsiveness through activation of apoptosis

  2007cites this paper
• Absence of p53 Enhances Growth Defects and Etoposide Sensitivity of Human Cells Lacking the Bloom Syndrome Helicase BLM

  2007cites this paper
• Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.

  2007cites this paper
• Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells

  2007cites this paper
• The unfolded protein response and cancer: a brighter future unfolding?

  2007cites this paper
• Topoisomerase inhibitors as therapeutic weapons

  2007cites this paper
• Bioassays for Activity

  2006cites this paper
• Association between Immunohistochemical Expression of Topoisomerase IIα, Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer

  2006cites this paper
• Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

  2005cites this paper
• Characterization of human NSCLC cell line with innate etoposide‐resistance mediated by cytoplasmic localization of topoisomerase II alpha

  2005cites this paper
• Mechanisms of Action of Cancer Chemotherapeutic Agents: Topoisomerase Inhibitors

  2005cites this paper
• Combining Etoposide and Dexrazoxane Synergizes with Radiotherapy and Improves Survival in Mice with Central Nervous System Tumors

  2005cites this paper
• Dexrazoxane Protects against Myelosuppression from the DNA Cleavage–Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin

  2005cites this paper
• QSAR studies of 20(S)-camptothecin analogues as antitumor agents

  2005cites this paper
• Bringing molecular prognosis and prediction to the clinic.

  2005cites this paper
• Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase IIα Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs

  2005cites this paper
• Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase

  2005cites this paper
• The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor bearing mice

  2005cites this paper
• A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II

  2004cites this paper
• The role of the unfolded protein response in tumour development: friend or foe?

  2004cites this paper
• Loss of Nonhomologous End Joining Confers Camptothecin Resistance in DT40 Cells

  2004cites this paper
• Etoposide: discovery and medicinal chemistry.

  2004cites this paper
• DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs

  2004cites this paper
• Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells.

  2004cites this paper
• Enhanced oligonucleotide-directed gene targeting in mammalian cells following treatment with DNA damaging agents.

  2004cites this paper
• Excellent Response to Gemcitabine in a Massively Pre-Treated Woman with Extensive Cutaneous Involvement after Recurrence of Breast Cancer

  2004cites this paper
• A Mutation in Human Topoisomerase II α Whose Expression Is Lethal in DNA Repair-deficient Yeast Cells*

  2004cites this paper
• An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents.

  2004cites this paper
• The role of ABC transporters in clinical practice.

  2003cites this paper
• Consequence of Hoechst 33342-mediated Leishmania DNA topoisomerase-I inhibition on parasite replication

  2003cites this paper
• Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.

  2003cites this paper
• Increase in mitotic recombination in diploid cells of Aspergillus nidulans in response to ethidium bromide

  2003cites this paper
• Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.

  2003cites this paper
• Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193

  2003cites this paper
• DNA Topoisomerases in Cancer Therapy

  2003cites this paper
• Cell-cycle-dependent three-dimensional redistribution of nuclear proteins, P 120, pKi-67, and SC 35 splicing factor, in the presence of the topoisomerase I inhibitor camptothecin.

  2003cites this paper
• Effects of ER-37328 on primary tumor, liver metastasis, and life span in a murine colon 38 orthotopic transplantation model.

  2003influential citation
• Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms

  2003cites this paper
• DNA Topoisomerase II as a Target for Cancer Chemotherapy

  2002cites this paper